Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2003-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 12700281
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide

  2004cited by this paper
• Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.

  2002cited by this paper
• Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.

  2002cited by this paper
• Poly(ADP‐ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells

  2002cited by this paper
• Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.

  2002cited by this paper
• Poly(ADP-ribose) Polymerase-2 (PARP-2) Is Required for Efficient Base Excision DNA Repair in Association with PARP-1 and XRCC1*

  2002cited by this paper
• BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity.

  2002cited by this paper
• The world according to PARP.

  2001cited by this paper
• p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells.

  2001cited by this paper
• Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

  2001cited by this paper
• The response of Parp knockout mice against DNA damaging agents.

  2000cited by this paper
• Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.

  2000cited by this paper
• A quantitative method for determining in vivo activation of PARP and biological activity of inhibitors of the enzyme

  2000cited by this paper
• Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

  2000cited by this paper
• Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions.

  1999cited by this paper
• Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

  1999cited by this paper
• Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines

  1999cited by this paper
• Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.

  1999cited by this paper
• Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization.

  1999cited by this paper
• Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.

  1999cited by this paper
• Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

  1998cited by this paper
• DNA repair, cell cycle progression and cell death following camptothecin treatment in two murine lymphoma L5178Y sublines

  1998cited by this paper
• Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).

  1998cited by this paper
• DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines.

  1998cited by this paper
• Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).

  1998cited by this paper
• Regulation and deregulation of G2 checkpoint proteins with cisplatin.

  1998cited by this paper
• Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells.

  1997cited by this paper
• CPT‐11 in human colon‐cancer cell lines and xenografts: Characterization of cellular sensitivity determinants

  1997influential reference
• Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.

  1997cited by this paper
• The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.

  1995cited by this paper
• Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors.

  1995cited by this paper
• Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.

  1995cited by this paper
• Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.

  1994cited by this paper
• Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment.

  1993cited by this paper
• Enhancement of bleomycin activity by 3-aminobenzamide, a poly (ADP-ribose) synthesis inhibitor, in vitro and in vivo.

  1988cited by this paper
• Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells.

  1987cited by this paper

• Transcription–replication conflicts underlie sensitivity to PARP inhibitors

  2024cites this paper
• Evolution of the Development of PARP Inhibitors.

  2023cites this paper
• Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials

  2023cites this paper
• NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

  2023cites this paper
• Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer

  2022cites this paper
• Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents

  2021cites this paper
• Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers

  2021cites this paper
• Transcriptomics reveals in vivo efficacy of PARP inhibitor combinatorial synergy with platinum-based chemotherapy in human non-small cell lung carcinoma models

  2021cites this paper
• Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications

  2020cites this paper
• Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome

  2020cites this paper
• Progress and challenges in gastroesophageal cancer.

  2020cites this paper
• Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair

  2020cites this paper
• PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy

  2019cites this paper
• PARP Inhibition to Enhance Response to Chemotherapy

  2019cites this paper
• Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk

  2019cites this paper
• Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.

  2018cites this paper
• Identification of amentoflavone as a potent highly selective PARP-1 inhibitor and its potentiation on carboplatin in human non-small cell lung cancer.

  2018cites this paper
• Poly ADP-ribose polymerase inhibition suppresses cisplatin toxicity in chronic myeloid leukemia cells

  2017cites this paper
• PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.

  2017cites this paper
• 17 BRCA 2 Mutations and Consequences for DNA Repair

  2017cites this paper
• Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies

  2017cites this paper
• A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.

  2017cites this paper
• Enzymes in the Base Excision Repair Pathway as Targets for Small Molecule Mediated Therapeutics

  2017cites this paper
• Targeting DNA Damage Response Pathways in Cancer

  2017cites this paper
• Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer.

  2017cites this paper
• A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

  2017cites this paper
• A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.

  2017cites this paper
• Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors

  2016cites this paper
• Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors

  2016cites this paper
• Graphical models for de novo and pathway-based network prediction over multi-modal high-throughput biological data

  2016influential citation
• DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications.

  2016cites this paper
• PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention.

  2016cites this paper
• PARP inhibitor combination therapy.

  2016cites this paper
• Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors

  2016cites this paper
• An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma

  2016cites this paper
• A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.

  2016cites this paper
• Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

  2016influential citation
• A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale

  2016cites this paper
• Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors

  2016cites this paper
• An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors

  2016cites this paper
• PI3K-AKT-mTOR Pathway Cooperates with the DNA Damage Repair Pathway: Carcinogenesis in Triple-Negative Breast Cancers and Beyond

  2016cites this paper
• PARP1 Inhibitors: antitumor drug design

  2015cites this paper
• PARP Enzymes are Potential Targets for Cancer Chemotherapy

  2015cites this paper
• Inhibitor Inhibits DNA Repair Vitro.

  2015cites this paper
• The Novel Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro.

  2015cites this paper
• Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

  2015cites this paper
• Inhibits DNA Repair

  2015cites this paper
• Clinical Trials of PARP Inhibitors with Chemotherapy

  2015cites this paper
• InhibitorRucaparib inOrthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

  2015cites this paper
• The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro

  2015cites this paper
• Introduction to PARPi Clinical Trials and Future Directions

  2015cites this paper
• Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase

  2014cites this paper
• A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity

  2014cites this paper
• ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy

  2014cites this paper
• Small Molecule Therapeutics The Use of Olaparib ( AZD 2281 ) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad 51-Mediated Repair of DNA Double-Strand Breaks

  2014cites this paper
• Poly (ADP-ribose) Polymerase Inhibitors in Cancer Treatment

  2014cites this paper
• A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis

  2014cites this paper
• PARP-1 inhibitors and radiotherapy sensitivity: future prospects for therapy?

  2014cites this paper
• PARP inhibitors for anticancer therapy.

  2014cites this paper
• From old alkylating agents to new minor groove binders.

  2014cites this paper
• Inhibition of DNA Repair as a Therapeutic Target

  2014cites this paper
• Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

  2014cites this paper
• Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

  2014cites this paper
• Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside.

  2014cites this paper
• Effect of DNA repair deficiencies on the cytotoxicity of drugs used in cancer therapy - a review.

  2014cites this paper
• The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks

  2014cites this paper
• TFPI‐2 Downregulates Multidrug Resistance Protein in 5‐FU‐Resistant Human Hepatocellular Carcinoma BEL‐7402/5‐FU Cells

  2013cites this paper
• Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors.

  2013cites this paper
• Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.

  2013cites this paper
• Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

  2013influential citation
• Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.

  2013cites this paper
• The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies

  2013cites this paper
• Clinical Significance of PARP-1 Inhibitors in Cancer Chemotherapy

  2013cites this paper
• Current and future directions for Phase II trials in high-grade glioma

  2013cites this paper
• Synthetic lethality and functional study of DNA repair defects in ERCC1-deficient non-small-cell lung cancer

  2013cites this paper
• “Synthetic Lethality”: Molecular Co-targeting to Restore the DNA Repair Mechanisms in Prostate Cancer Cells

  2013cites this paper
• Poly(ADP-ribose) polymerase inhibitors as cancer therapy.

  2013cites this paper
• On the Track to Cancer Therapy: Paving New Ways with Ruthenium Organometallics

  2013cites this paper
• Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer

  2013influential citation
• DNA repair systems in rhabdomyosarcoma.

  2013cites this paper
• Synthetic lethality and cancer: cohesin and PARP at the replication fork.

  2013cites this paper
• Serendipitous Discovery of a Prodrug of a PARP‐1 Inhibitor

  2013cites this paper
• Current state-of-the-art therapy for advanced squamous cell lung cancer.

  2013cites this paper
• Base excision repair of radiation-induced DNA damage in mammalian cells

  2013cites this paper
• Selective tumor killing based on specific DNA-damage response deficiencies

  2012cites this paper
• Targeted therapy for brain tumours: role of PARP inhibitors.

  2012cites this paper
• A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors

  2012cites this paper
• Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors

  2012cites this paper
• Molecular mechanisms of temozolomide resistance in glioblastoma multiforme

  2012cites this paper
• The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

  2012cites this paper
• Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.

  2012cites this paper
• DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets.

  2012cites this paper
• Novel targeted therapies in head and neck cancer

  2012cites this paper
• Targeting DNA repair and the cell cycle in glioblastoma

  2012cites this paper
• [RuII(η⁵-C₅H₅)(bipy)(PPh₃)]⁺, a promising large spectrum antitumor agent: cytotoxic activity and interaction with human serum albumin.

  2012cites this paper
• Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma

  2012cites this paper
• Novel Therapies in Glioblastoma

  2012cites this paper
• Synthesis and evaluation of thiopyrano[3,4-c]quinoline-9-carboxamide derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)

  2012cites this paper
• Current and Future Management Strategies for Relapsed or Progressive Hepatoblastoma

  2012cites this paper
• PARP1 expression in breast cancer and effects of its inhibition in preclinical models

  2012cites this paper